Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

167

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

167 results for “immunomodulation;”

Learn how ShareScore rates datasets ↗
zenodo36/100

Recombinant Costimulatory Fusion Proteins as Functional Immunomodulators Enhance Antitumor Activity in Murine B16F10 Melanoma

<p>Cancer immunotherapy has emerged as an important therapeutic modality in preclinical and clinical oncology. Blocking inhibitory signaling and engaging stimulatory signaling enable some patients to produce an efficient antitumor response. In this work, we demonstrate unique and unexpected immunomodulatory features of different costimulatory ligand proteins with no combination of tumor-associated products, which bridge innate and adaptive immune responses against cancer in preventive as well as therapeutic efficacy.</p>

opencc-by-4.0Apr 2020View details →
zenodo36/100

Lipoic acid protects the central nervous system by immunomodulation and antioxidation

<p>Lipoic acid protects the central nervous system by immunomodulation and antioxidation.&nbsp;In the periphery, LA prevents inflammatory cells from crossing the BBB&nbsp;and protects brain endothelial cells. In the CNS, LA&nbsp;inhibits the activity of T cells/microglia,&nbsp;decreases the expression of TNF-&alpha; and IFN-&gamma;, and&nbsp;neutralizes ROS and NO.</p>

opencc-by-4.0Dec 2021View details →
zenodo36/100

CD4+ T cells re-wire granuloma cellularity and regulatory networks, promoting immunomodulation following Mtb reinfection

<p>Here we include the necessary .ipynb, .h5ad, and .rds (used for cell-cell interaction analyses) files used in our work: "Immunomodulatory re-wiring of granuloma cellularity and regulatory networks by CD4 T cells following Mtb reinfection"</p>

opencc-by-4.0May 2024View details →
ClinicalTrials.gov36/100

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator

ClinicalTrials.gov study NCT00094458. IPD Sharing: Not stated. Countries: 15. Publications: 7.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

ClinicalTrials.gov study NCT00976404. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

ClinicalTrials.gov study NCT02338999. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia

ClinicalTrials.gov study NCT01793935. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

ClinicalTrials.gov study NCT01802073. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Immunomodulation Following Transfusion

ClinicalTrials.gov study NCT00810810. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation

ClinicalTrials.gov study NCT01841632. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

ClinicalTrials.gov study NCT04317040. IPD Sharing: YES. Countries: 1. Publications: 8.

controlledIPD-YESFeb 2026View details →
dryad32/100

Medium-chain fatty acids suppress lipotoxicity-induced hepatic fibrosis via the immunomodulating receptor GPR84

<p><span>Medium-chain triglycerides (MCTs), which consist of medium-chain fatty acids (MCFAs), are unique forms of dietary fat with various health benefits. GPR84 acts as a receptor for MCFAs (especially C10:0 and C12:0); however, GPR84 is still considered an orphan receptor, and </span><span>the</span><span> nutritional signaling of endogenous and dietary MCFAs via GPR84 remains unclear. Here, we showed that endogenous MCFA-mediated GPR84-signaling protected hepatic functions from diet-induced lipotoxicity. Under high-fat diet (HFD) conditions, GPR84-deficient mice exhibited </span><span>non-alcoholic steatohepatitis (NASH) and the progression of hepatic fibrosis but not steatosis.</span> <span>With markedly increased hepatic MCFA levels under HFD, GPR84 suppressed lipotoxicity-induced macrophage over-activation. Thus, GPR84 is an immunomodulating receptor that suppresses excessive dietary fat intake-induced toxicity by sensing increases in MCFAs. Additionally, administering MCTs, MCFAs (C10:0 or C12:0, but not C8:0), or GPR84 agonists effectively prevented NASH in mouse models. Exogenous GPR84 stimulation is therefore a breakthrough strategy for treating NASH</span><span>.</span></p>

opencc-zeroJun 2022View details →
ClinicalTrials.gov32/100

Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)

ClinicalTrials.gov study NCT03145220. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.

ClinicalTrials.gov study NCT00341328. IPD Sharing: Not stated. Countries: 1. Publications: 10.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

ClinicalTrials.gov study NCT00645749. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Identification of Immunomodulators Associated With Atrial Fibrillation Reporting: Analysis of the WHO Pharmacovigilance Database

ClinicalTrials.gov study NCT06095791. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients

ClinicalTrials.gov study NCT03150134. IPD Sharing: YES. Countries: 1. Publications: 10.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

US Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation

ClinicalTrials.gov study NCT04796363. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Immunomodulation by Zinc Supplementation in Children With Pneumonia

ClinicalTrials.gov study NCT03690583. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent

ClinicalTrials.gov study NCT06075849. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record